Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-3-6
|
pubmed:abstractText |
Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized placebo-controlled trial, 21 children received one dose of PFP-2 (purified fusion [F] protein) vaccine or influenza vaccine (placebo). Children were followed for adverse reactions and RSV illness over two respiratory seasons. Sera were obtained for determination of IgG titers to RSV F protein and neutralizing antibody titers before and 1, 6, and 12 months after vaccination. Adverse reactions were few. Four-fold F protein rises occurred in 9 of 10 PFP-2 and 0 of 11 placebo recipients. Six PFP-2 recipients had low prevaccination neutralizing antibody titers (< 1:450); all had 4-fold rises. By 12 months, F protein and neutralizing antibody titers in all 21 children were similar. RSV illness occurred in 6 of 11 placebo versus 1 of 10 PFP-2 recipients (P = .06); 1 placebo child required hospitalization. PFP-2 vaccine appears safe and immunogenic and may protect children with bronchopulmonary dysplasia against serious RSV disease on reinfection.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/HN Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Influenza Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/attachment protein G
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0022-1899
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
177
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
467-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9466539-Antibodies, Viral,
pubmed-meshheading:9466539-Bronchopulmonary Dysplasia,
pubmed-meshheading:9466539-Child, Preschool,
pubmed-meshheading:9466539-Double-Blind Method,
pubmed-meshheading:9466539-HN Protein,
pubmed-meshheading:9466539-Hospitalization,
pubmed-meshheading:9466539-Humans,
pubmed-meshheading:9466539-Immunoglobulin G,
pubmed-meshheading:9466539-Infant, Newborn,
pubmed-meshheading:9466539-Influenza Vaccines,
pubmed-meshheading:9466539-Neutralization Tests,
pubmed-meshheading:9466539-Prospective Studies,
pubmed-meshheading:9466539-Respiratory Syncytial Virus Infections,
pubmed-meshheading:9466539-Seasons,
pubmed-meshheading:9466539-Viral Envelope Proteins,
pubmed-meshheading:9466539-Viral Proteins,
pubmed-meshheading:9466539-Viral Vaccines
|
pubmed:year |
1998
|
pubmed:articleTitle |
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
|
pubmed:affiliation |
Department of Pediatrics, University of Colorado, School of Medicine, Denver, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|